Oculis Holding AG (NASDAQ:OCS) Given Consensus Rating of “Buy” by Analysts

Oculis Holding AG (NASDAQ:OCS) has earned a consensus recommendation of “Buy” from the five analysts that are presently covering the firm, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $29.20.

Several research analysts have recently issued reports on OCS shares. Bank of America cut their target price on shares of Oculis from $21.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, June 11th. Chardan Capital restated a “buy” rating and issued a $30.00 target price on shares of Oculis in a report on Tuesday, June 11th. Robert W. Baird raised their target price on shares of Oculis from $35.00 to $37.00 and gave the stock an “outperform” rating in a report on Tuesday, June 11th. Finally, HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Oculis in a report on Wednesday, August 28th.

Oculis Stock Up 4.3 %

Shares of NASDAQ OCS opened at $13.20 on Tuesday. Oculis has a one year low of $9.05 and a one year high of $14.47. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.27 and a quick ratio of 5.27. The firm’s 50 day simple moving average is $11.92 and its two-hundred day simple moving average is $11.87. The stock has a market capitalization of $534.65 million, a P/E ratio of -7.42 and a beta of 0.30.

Oculis (NASDAQ:OCS) last issued its earnings results on Tuesday, August 27th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.13). Oculis had a negative return on equity of 61.33% and a negative net margin of 7,679.05%. The firm had revenue of $0.27 million during the quarter, compared to the consensus estimate of $0.28 million. As a group, analysts expect that Oculis will post -2.19 EPS for the current fiscal year.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.